| Article Access Statistics | | | Viewed | 5234 | | | Printed | 156 | | | Emailed | 0 | | | PDF Downloaded | 246 | | | Comments | [Add] | | | Cited by others | 8 | | |
|
Click on image for details.
|
|
| LETTERS |
|
|
|
| Year : 2007 | Volume
: 53
| Issue : 3 | Page : 218 |
Worsening of tardive dyskinesia due to clozapine therapy
J Raguraman1, J Vijaysagar2
1 SHO, Sheffield Care Trust, S5 7JT, United Kingdom
2 Department of Psychiatry, S.V. Medical College, Tirupati, India
Correspondence Address:
J Raguraman
SHO, Sheffield Care Trust, S5 7JT
United Kingdom
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0022-3859.33874
How to cite this article:
Raguraman J, Vijaysagar J. Worsening of tardive dyskinesia due to clozapine therapy. J Postgrad Med 2007;53:218 |
Sir,
We report an interesting case of worsening of tardive dyskinesia (TD) due to clozapine therapy.
Mr S, a 28-year-old man, presented to us with six years duration of continuous illness characterized by fearfulness, poor sleep, auditory hallucinations, delusion of control and social withdrawal. He carried a diagnosis of paranoid schizophrenia. He also suffered from asthma and was on salbutomol inhaler as and when required. His father was a chronic alcoholic. There was no significant past or family history of psychiatric illness. He was treated with chlorpromazine 600 mg/day and changed over to risperidone three years later as he developed severe postural hypotension. In addition to this, he was also given Sodium Valproate 750 mg/day to control his agitation and aggression.
Since he showed good improvement in his mental state and global functioning, he was maintained on 6 mg of Risperidone. Two years later he began to suffer from TD of upper limbs and oro-facial dyskinesia. His baseline assessment of abnormal involuntary movement scale (AIMS) revealed a score of 12. [1] Risperidone was slowly tapered and stopped over two weeks time. He was started on clozapine as he satisfied the criteria for treatment-resistant schizophrenia and it was also thought that this would help to cure TD.
EEG, ECG, full blood count and LFTs were carried out as a pre-clozapine workup. FBC and ECG were carried out once a week to rule out any potential side-effects like myocarditis, cardiomyopathy and neutropenia.
The dose of clozapine was gradually titrated to 300 mg/day over a period of two months. Patient was followed up once a week and evaluated on AIMS. At the end of four weeks, patient had worsening of TD (AIMS score 24). He showed a total score of +5 in Naranjos algorithm to explain the cause and effect relationship. [2] Clozapine was tapered and stopped. He was commenced on Amisulpiride and increased to 800 mg/day along with semisodium valproate 1500 mg/day in two months time. Further follow-up over a six-month period revealed an improvement of TD (AIMS score 14).
Tardive dyskinesia is an important clinical problem which has been shown to have a causal relationship with the dopamine hypersensitivity in basal ganglia. Atypical antipsychotics have a reduced liability for inducing TD. Passive resolution of TD may be facilitated in some patients by the use of these agents. [3] There are few evidences in literature that clozapine may induce TD. Ertugrul et al raise the possibility that clozapine can induce dyskinesia.[4] In a study of 28 patients with no prior history of TD who were treated with clozapine for one year, two patients were later rated as having mild TD. [5] One of the reasons for worsening of TD in clozapine-treated patients could be due to previous treatment with typical antipsychotic.
It is unclear whether clozapine has a direct worsening effect on TD. Clozapine may induce TD in extremely rare cases, which cannot be excluded. This study involves only a single individual and therefore may not be representative of the general group. In future, this needs further exploration by systematically analyzing a large sample with a control group.
| :: References | |  |
| 1. | Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988;39:1172-7.  [PUBMED] |
| 2. | Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. [PUBMED] |
| 3. | Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002;63:12-9. |
| 4. | Ertugrul A, Demir B. Clozapine-induced tardive dyskinesia: A case report. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:633-5. [PUBMED] [FULLTEXT] |
| 5. | Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does Clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54:327-30. [PUBMED] |
| This article has been cited by | | 1 |
Tardive dyskinesia in Chinese patients with schizophrenia: Prevalence, clinical correlates and relationship with cognitive impairment |
|
| Qilin Liang, Dongmei Wang, Huixia Zhou, Dachun Chen, Meihong Xiu, Lixia Cui, Xiangyang Zhang | | Journal of Psychiatric Research. 2022; 151: 181 | | [Pubmed] | [DOI] | | | 2 |
Clozapine and tardive movement disorders: A review |
|
| Nandita Hazari,Natasha Kate,Sandeep Grover | | Asian Journal of Psychiatry. 2013; | | [Pubmed] | [DOI] | | | 3 |
tardive dyskinesia: clinical presentation and treatment |
|
| van harten, p.n. and tenback, d.e. | | international review of neurobiology. 2011; 98: 187-210 | | [Pubmed] | | | 4 |
Tardive dyskinesia with clozapine dose reduction or withdrawal dyskinesia |
|
| Praharaj, S.K. | | Indian Journal of Pharmacology. 2011; 43(1): 93 | | [Pubmed] | | | 5 |
Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs |
|
| Tarsy, D., Lungu, C., Baldessarini, R.J. | | Handbook of Clinical Neurology. 2011; 100: 601-616 | | [Pubmed] | | | 6 |
Indian research: Focus on clozapine |
|
| Grover, S., Dutt, A., Avasthi, A. | | Indian Journal of Psychiatry. 2010; 52(2): 168-173 | | [Pubmed] | | | 7 |
Indian research: Focus on clozapine |
|
| Sandeep Grover, Alakananda Dutt, Ajit Avasthi | | Indian Journal of Psychiatry. 2010; 52(2): 168 | | [Pubmed] | [DOI] | | | 8 |
Current awareness: Pharmacoepidemiology and drug safety |
|
| | | Pharmacoepidemiology and Drug Safety. 2008; 17(5): i | | [VIEW] | [DOI] | |
|
|
|
|
|
|
|
|
